<DOC>
	<DOCNO>NCT01920633</DOCNO>
	<brief_summary>This single visit study people Down syndrome age 12-30 attend clinical center undergo assessment evaluate eligibility potential enrollment future BP27832 Phase II clinical study evaluate efficacy , safety tolerability RG1662 . Study participant may withdraw study time reason .</brief_summary>
	<brief_title>A Screening Protocol Assess Adults Adolescents With Down Syndrome Eligibility For Upcoming Study RG1662 ( Study BP27832 )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>Study participant assess follow criterion require meet order participate future Phase II study BP27832 : Males females 1230 year age ( 1830 US ) Clinical diagnosis Down syndrome ( trisomy 21 ) document chromosomal analysis ( karyotyping ) BMI 1840 1530 kg/m2 inclusive adult adolescent respectively Ability complete Clinical Evaluation Language Fundamentals ( CELF ) preschool 2 word class task Study participant willing assent consent participate Parent guardian willing give write informed consent Study participant must parent , reliable caregiver agree accompany study participant clinic visit treatment study , BP27832 The parent caregiver must constant reliable informant sufficient contact study participant detail knowledge study participant 's adaptive functioning order able complete assessment accurately Study participant must verbal able understood time must use form communication , sign , symbol board device primary form communication Study participant must sufficient vision hear participate study evaluation Study participant antiepileptic treatment must stable dos 4 week prior enrollment treatment protocol In future Phase II study , study participant must meet following criterion : Study participant severe lactose intolerance Study participant moderate severe Obstructive Sleep Apnea ( OSA ) define ApneaHypopnea Index ( AHI ) ( &gt; 15 event per hour well control positive airway pressure therapy stable setting ) 6 week prior screen visit Study participant history malignancy consider likely cured Personal history infantile spasm , epilepsy , severe head trauma Central Nervous System ( CNS ) infection ( e.g . meningitis ) , exception single isolate febrile seizure Study participant history epilepsy within last 2 year . Evidence active , clinically significant , unstable gastrointestinal , renal , hepatic , endocrine cardiovascular system disease Study participant current Diagnostic Statistical Manual Mental Disorders ( DSM5 ) diagnosis primary psychiatric diagnosis ( include autism spectrum disorder ) . Diagnoses secondary , intellectual disability , attention deficit hyperactivity disorder , depression conduct disorder allow long consider stable interfere conduct future treatment study Study participant history suicide attempt deliberate selfharm due suicidal ideation include . Suicidal ideation ( even absence suicide attempt deliberate selfharm ) 6 month prior screen Concomitant use exclude approve unapproved medication Personal family history congenital long QT syndrome History hepatitis C know Human Immunodeficiency Virus ( HIV ) infection Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>